CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing
Retrieved on:
Friday, November 12, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, SITC, Macrophage, Science, Therapy, MD, TLR, Cytokine, Antigen, Antigen presentation, CEO, CER, Immune system, APC, TCR, Society, B cell, CERS, Lymphatic system, Neoplasm, Abstract, Immunotherapy, Cero, CAR, Vaccine, CERo’s Platform Technology, CERo Therapeutics, CERO’S PLATFORM TECHNOLOGY, CERO THERAPEUTICS
CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, today presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor (CER) T cells.
Key Points:
- CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, today presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor (CER) T cells.
- One of the limitations of activated T cells is their poor ability to present antigens due to inefficient antigen capture.
- Further, CER T cells exhibited abilities to capture tumor cell fragments and induce expression of T-cell activation markers and cytokines.
- CER T cells containing a toll-like receptor (TLR) domain also showed enhanced ability to present exogenous antigen and activate antigen-specific TCR T cells.